 Ihab Kamel
Concepts (658)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Neoplasms | 125 | 2025 | 776 | 21.800 |
Why?
| | Carcinoma, Hepatocellular | 75 | 2025 | 372 | 16.610 |
Why?
| | Chemoembolization, Therapeutic | 43 | 2024 | 89 | 12.140 |
Why?
| | Diffusion Magnetic Resonance Imaging | 48 | 2025 | 155 | 11.070 |
Why?
| | Magnetic Resonance Imaging | 141 | 2025 | 3904 | 10.470 |
Why?
| | Pancreatic Neoplasms | 34 | 2024 | 928 | 5.850 |
Why?
| | Cholangiocarcinoma | 19 | 2024 | 108 | 5.300 |
Why?
| | Contrast Media | 60 | 2025 | 497 | 4.790 |
Why?
| | Image Enhancement | 29 | 2018 | 200 | 4.580 |
Why?
| | Tomography, X-Ray Computed | 68 | 2025 | 2769 | 4.340 |
Why?
| | Carcinoma, Pancreatic Ductal | 14 | 2024 | 293 | 4.050 |
Why?
| | Image Interpretation, Computer-Assisted | 23 | 2025 | 288 | 3.880 |
Why?
| | Bile Duct Neoplasms | 15 | 2023 | 131 | 3.850 |
Why?
| | Liver | 38 | 2025 | 1896 | 3.630 |
Why?
| | Neuroendocrine Tumors | 12 | 2021 | 119 | 3.160 |
Why?
| | Liver Cirrhosis | 20 | 2024 | 287 | 3.030 |
Why?
| | Elasticity Imaging Techniques | 9 | 2023 | 58 | 2.800 |
Why?
| | Liver Diseases | 17 | 2023 | 305 | 2.770 |
Why?
| | Pancreatic Cyst | 12 | 2023 | 50 | 2.590 |
Why?
| | Arrhythmogenic Right Ventricular Dysplasia | 16 | 2022 | 60 | 2.450 |
Why?
| | Tumor Burden | 14 | 2024 | 325 | 2.380 |
Why?
| | Retrospective Studies | 104 | 2026 | 17291 | 2.370 |
Why?
| | Cholangitis, Sclerosing | 5 | 2020 | 61 | 2.340 |
Why?
| | Middle Aged | 178 | 2026 | 36215 | 2.340 |
Why?
| | Gadolinium DTPA | 20 | 2025 | 70 | 2.310 |
Why?
| | Humans | 335 | 2026 | 145474 | 2.170 |
Why?
| | Algorithms | 20 | 2025 | 1845 | 2.080 |
Why?
| | Aged | 142 | 2025 | 26153 | 2.080 |
Why?
| | Cystadenoma, Serous | 3 | 2024 | 18 | 1.940 |
Why?
| | Pancreatitis | 8 | 2023 | 146 | 1.930 |
Why?
| | Sensitivity and Specificity | 37 | 2025 | 1997 | 1.920 |
Why?
| | Male | 194 | 2026 | 72842 | 1.810 |
Why?
| | Female | 205 | 2026 | 78844 | 1.790 |
Why?
| | Reproducibility of Results | 41 | 2025 | 3413 | 1.760 |
Why?
| | Positron-Emission Tomography | 10 | 2023 | 343 | 1.720 |
Why?
| | Pancreas | 13 | 2024 | 341 | 1.700 |
Why?
| | Esophageal Neoplasms | 13 | 2025 | 348 | 1.670 |
Why?
| | Treatment Outcome | 60 | 2025 | 11772 | 1.550 |
Why?
| | Colorectal Neoplasms | 10 | 2021 | 866 | 1.530 |
Why?
| | Spleen | 4 | 2020 | 508 | 1.520 |
Why?
| | Carcinoma, Renal Cell | 6 | 2024 | 230 | 1.480 |
Why?
| | Adult | 120 | 2026 | 40777 | 1.480 |
Why?
| | Diagnosis, Differential | 27 | 2025 | 1508 | 1.470 |
Why?
| | Cholangiopancreatography, Magnetic Resonance | 7 | 2020 | 24 | 1.460 |
Why?
| | Incidental Findings | 5 | 2024 | 81 | 1.460 |
Why?
| | Kidney Neoplasms | 7 | 2025 | 413 | 1.460 |
Why?
| | Splenic Diseases | 3 | 2019 | 9 | 1.440 |
Why?
| | Iron Overload | 4 | 2024 | 19 | 1.380 |
Why?
| | Aged, 80 and over | 55 | 2024 | 8333 | 1.350 |
Why?
| | Adenoma, Liver Cell | 4 | 2024 | 4 | 1.340 |
Why?
| | Embolization, Therapeutic | 11 | 2022 | 242 | 1.340 |
Why?
| | Diagnostic Imaging | 15 | 2024 | 337 | 1.250 |
Why?
| | Lymphatic Metastasis | 5 | 2024 | 331 | 1.210 |
Why?
| | Image Processing, Computer-Assisted | 16 | 2025 | 779 | 1.190 |
Why?
| | Angiomyolipoma | 3 | 2018 | 21 | 1.180 |
Why?
| | Ultrasonography | 7 | 2025 | 785 | 1.160 |
Why?
| | Ureteral Obstruction | 2 | 2020 | 63 | 1.160 |
Why?
| | Biomarkers, Tumor | 9 | 2025 | 1321 | 1.150 |
Why?
| | Imaging, Three-Dimensional | 15 | 2025 | 583 | 1.140 |
Why?
| | Hepatectomy | 18 | 2021 | 274 | 1.130 |
Why?
| | Predictive Value of Tests | 25 | 2025 | 2121 | 1.130 |
Why?
| | Focal Nodular Hyperplasia | 5 | 2018 | 7 | 1.120 |
Why?
| | Liver Transplantation | 16 | 2025 | 826 | 1.100 |
Why?
| | Uterine Neoplasms | 4 | 2023 | 98 | 1.100 |
Why?
| | Magnetic Resonance Angiography | 4 | 2025 | 251 | 1.100 |
Why?
| | Rectal Neoplasms | 6 | 2024 | 159 | 1.090 |
Why?
| | Adipose Tissue | 7 | 2024 | 645 | 1.090 |
Why?
| | Organometallic Compounds | 4 | 2018 | 113 | 1.080 |
Why?
| | Adenoma | 4 | 2024 | 218 | 1.070 |
Why?
| | Prognosis | 26 | 2024 | 4316 | 1.060 |
Why?
| | Neoadjuvant Therapy | 10 | 2025 | 465 | 1.050 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 10 | 2024 | 1963 | 1.040 |
Why?
| | Neoplasm Staging | 20 | 2024 | 1471 | 1.040 |
Why?
| | Kidney Diseases | 3 | 2020 | 425 | 1.030 |
Why?
| | Bile Ducts, Intrahepatic | 13 | 2023 | 63 | 1.020 |
Why?
| | ROC Curve | 18 | 2024 | 617 | 1.020 |
Why?
| | Kidney | 10 | 2026 | 1497 | 0.980 |
Why?
| | Fibrosis | 10 | 2026 | 559 | 0.960 |
Why?
| | Yttrium Radioisotopes | 5 | 2022 | 63 | 0.960 |
Why?
| | Survival Rate | 19 | 2024 | 2090 | 0.950 |
Why?
| | Cardiomyopathy, Hypertrophic | 9 | 2018 | 143 | 0.950 |
Why?
| | Carcinoma | 6 | 2023 | 225 | 0.920 |
Why?
| | Leiomyoma | 3 | 2023 | 61 | 0.890 |
Why?
| | Urinary Bladder Neoplasms | 7 | 2022 | 258 | 0.890 |
Why?
| | Renal Artery | 3 | 2025 | 43 | 0.890 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 389 | 0.880 |
Why?
| | Coronavirus Infections | 2 | 2020 | 383 | 0.880 |
Why?
| | Societies, Medical | 17 | 2025 | 899 | 0.870 |
Why?
| | Nomograms | 2 | 2024 | 59 | 0.870 |
Why?
| | Neoplasm Grading | 6 | 2024 | 310 | 0.850 |
Why?
| | Magnetic Resonance Spectroscopy | 8 | 2022 | 627 | 0.840 |
Why?
| | Infusions, Intra-Arterial | 6 | 2019 | 61 | 0.810 |
Why?
| | Adenomyosis | 1 | 2023 | 7 | 0.810 |
Why?
| | Uterine Artery Embolization | 1 | 2023 | 9 | 0.810 |
Why?
| | Gastrointestinal Neoplasms | 2 | 2019 | 73 | 0.800 |
Why?
| | Prospective Studies | 33 | 2025 | 8057 | 0.800 |
Why?
| | Gallbladder Neoplasms | 1 | 2023 | 20 | 0.800 |
Why?
| | Liver Regeneration | 6 | 2017 | 46 | 0.790 |
Why?
| | Doxorubicin | 9 | 2014 | 401 | 0.780 |
Why?
| | Leiomyosarcoma | 2 | 2022 | 29 | 0.780 |
Why?
| | Antineoplastic Agents | 10 | 2019 | 2214 | 0.770 |
Why?
| | Living Donors | 4 | 2021 | 282 | 0.760 |
Why?
| | Adenocarcinoma | 7 | 2020 | 925 | 0.740 |
Why?
| | Neoplasms | 7 | 2021 | 2906 | 0.740 |
Why?
| | Positron Emission Tomography Computed Tomography | 5 | 2025 | 117 | 0.700 |
Why?
| | Hemangioma | 4 | 2022 | 46 | 0.700 |
Why?
| | Evidence-Based Medicine | 13 | 2025 | 740 | 0.690 |
Why?
| | Immunotherapy | 2 | 2024 | 666 | 0.690 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 3 | 2019 | 223 | 0.680 |
Why?
| | Fluorodeoxyglucose F18 | 3 | 2022 | 161 | 0.670 |
Why?
| | Risk Assessment | 13 | 2024 | 3747 | 0.660 |
Why?
| | Inflammatory Bowel Diseases | 2 | 2023 | 364 | 0.660 |
Why?
| | Patient Safety | 1 | 2024 | 356 | 0.660 |
Why?
| | Meglumine | 3 | 2018 | 18 | 0.660 |
Why?
| | Catheter Ablation | 9 | 2018 | 355 | 0.660 |
Why?
| | Multidetector Computed Tomography | 6 | 2024 | 40 | 0.640 |
Why?
| | Lupus Nephritis | 3 | 2026 | 67 | 0.640 |
Why?
| | Obesity, Abdominal | 1 | 2020 | 47 | 0.630 |
Why?
| | Adenocarcinoma, Mucinous | 3 | 2018 | 76 | 0.620 |
Why?
| | Diffusion Tensor Imaging | 2 | 2021 | 75 | 0.620 |
Why?
| | Subcutaneous Fat | 1 | 2020 | 79 | 0.620 |
Why?
| | Vascular Diseases | 2 | 2017 | 252 | 0.620 |
Why?
| | Necrosis | 5 | 2021 | 244 | 0.610 |
Why?
| | Observer Variation | 9 | 2020 | 357 | 0.590 |
Why?
| | Young Adult | 33 | 2026 | 14218 | 0.590 |
Why?
| | Follow-Up Studies | 21 | 2022 | 5423 | 0.590 |
Why?
| | Radiology | 6 | 2019 | 174 | 0.580 |
Why?
| | Abdominal Pain | 5 | 2025 | 149 | 0.570 |
Why?
| | Gastrointestinal Stromal Tumors | 1 | 2019 | 41 | 0.560 |
Why?
| | Adenoma, Oxyphilic | 1 | 2018 | 7 | 0.560 |
Why?
| | Biomarkers | 10 | 2026 | 4295 | 0.550 |
Why?
| | Biliary Tract Diseases | 4 | 2019 | 33 | 0.550 |
Why?
| | Hepatic Artery | 3 | 2013 | 53 | 0.540 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2018 | 58 | 0.530 |
Why?
| | Angiography | 4 | 2013 | 208 | 0.530 |
Why?
| | Phenylurea Compounds | 3 | 2015 | 119 | 0.530 |
Why?
| | Niacinamide | 3 | 2015 | 104 | 0.520 |
Why?
| | Fatty Liver | 6 | 2017 | 253 | 0.520 |
Why?
| | Pancreatic Ducts | 2 | 2015 | 82 | 0.520 |
Why?
| | Betacoronavirus | 1 | 2020 | 288 | 0.520 |
Why?
| | Whole Body Imaging | 3 | 2018 | 29 | 0.510 |
Why?
| | Tachycardia, Ventricular | 5 | 2022 | 180 | 0.510 |
Why?
| | Actins | 1 | 2019 | 425 | 0.500 |
Why?
| | Defibrillators, Implantable | 6 | 2022 | 382 | 0.500 |
Why?
| | Biopsy | 7 | 2026 | 1082 | 0.500 |
Why?
| | Magnetic Resonance Imaging, Cine | 5 | 2022 | 214 | 0.500 |
Why?
| | Lymph Nodes | 5 | 2024 | 503 | 0.490 |
Why?
| | Response Evaluation Criteria in Solid Tumors | 3 | 2025 | 21 | 0.490 |
Why?
| | Cystadenoma, Mucinous | 1 | 2016 | 11 | 0.490 |
Why?
| | Early Detection of Cancer | 9 | 2024 | 485 | 0.480 |
Why?
| | Neoplasm Recurrence, Local | 8 | 2023 | 1149 | 0.480 |
Why?
| | Watchful Waiting | 1 | 2016 | 90 | 0.460 |
Why?
| | Heart Ventricles | 8 | 2018 | 756 | 0.460 |
Why?
| | Liver Function Tests | 4 | 2025 | 105 | 0.460 |
Why?
| | Adrenal Gland Neoplasms | 1 | 2016 | 98 | 0.450 |
Why?
| | Kaplan-Meier Estimate | 11 | 2018 | 969 | 0.450 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 3 | 2025 | 122 | 0.430 |
Why?
| | Sarcopenia | 6 | 2016 | 91 | 0.430 |
Why?
| | Leucovorin | 2 | 2024 | 98 | 0.420 |
Why?
| | Choledochal Cyst | 3 | 2022 | 17 | 0.420 |
Why?
| | Bile Ducts | 3 | 2019 | 68 | 0.420 |
Why?
| | Abdomen | 2 | 2013 | 142 | 0.420 |
Why?
| | Multimodal Imaging | 3 | 2023 | 129 | 0.420 |
Why?
| | Esophageal and Gastric Varices | 2 | 2024 | 36 | 0.410 |
Why?
| | United States | 33 | 2026 | 16098 | 0.410 |
Why?
| | Neoplasm Invasiveness | 4 | 2020 | 506 | 0.400 |
Why?
| | Fluorouracil | 2 | 2024 | 231 | 0.400 |
Why?
| | Biliary Tract Neoplasms | 1 | 2013 | 31 | 0.400 |
Why?
| | Aspartate Aminotransferases | 1 | 2013 | 85 | 0.400 |
Why?
| | Risk Factors | 27 | 2026 | 10885 | 0.390 |
Why?
| | Survival Analysis | 6 | 2019 | 1374 | 0.390 |
Why?
| | Proportional Hazards Models | 11 | 2018 | 1327 | 0.390 |
Why?
| | Alanine Transaminase | 1 | 2013 | 151 | 0.380 |
Why?
| | Choline | 2 | 2011 | 137 | 0.380 |
Why?
| | Organ Size | 6 | 2019 | 461 | 0.370 |
Why?
| | Phantoms, Imaging | 5 | 2021 | 159 | 0.370 |
Why?
| | Iron | 3 | 2024 | 357 | 0.370 |
Why?
| | Ventricular Fibrillation | 3 | 2018 | 64 | 0.370 |
Why?
| | Ventricular Function, Right | 3 | 2020 | 297 | 0.360 |
Why?
| | Death, Sudden, Cardiac | 5 | 2022 | 232 | 0.360 |
Why?
| | Practice Guidelines as Topic | 6 | 2024 | 1581 | 0.360 |
Why?
| | Models, Biological | 2 | 2016 | 1764 | 0.350 |
Why?
| | Lupus Erythematosus, Systemic | 2 | 2025 | 238 | 0.350 |
Why?
| | Authorship | 1 | 2012 | 49 | 0.350 |
Why?
| | Carcinoma in Situ | 3 | 2021 | 44 | 0.340 |
Why?
| | Area Under Curve | 3 | 2019 | 331 | 0.340 |
Why?
| | Liver Neoplasms, Experimental | 1 | 2011 | 26 | 0.340 |
Why?
| | Myocardial Perfusion Imaging | 3 | 2025 | 50 | 0.340 |
Why?
| | Ethiodized Oil | 3 | 2021 | 10 | 0.340 |
Why?
| | Endosonography | 5 | 2020 | 160 | 0.330 |
Why?
| | Cystadenoma | 3 | 2023 | 5 | 0.330 |
Why?
| | Publishing | 1 | 2012 | 114 | 0.330 |
Why?
| | Arrhythmias, Cardiac | 5 | 2022 | 355 | 0.330 |
Why?
| | Cohort Studies | 11 | 2024 | 6013 | 0.330 |
Why?
| | Embolism | 1 | 2011 | 48 | 0.320 |
Why?
| | Radiopharmaceuticals | 4 | 2019 | 205 | 0.320 |
Why?
| | Echo-Planar Imaging | 3 | 2023 | 24 | 0.320 |
Why?
| | Tomography, Spiral Computed | 4 | 2007 | 30 | 0.320 |
Why?
| | Angiomatosis | 1 | 2010 | 5 | 0.320 |
Why?
| | Non-alcoholic Fatty Liver Disease | 4 | 2021 | 265 | 0.310 |
Why?
| | SEER Program | 3 | 2024 | 229 | 0.310 |
Why?
| | Bevacizumab | 3 | 2021 | 168 | 0.310 |
Why?
| | Breast Neoplasms | 6 | 2021 | 2382 | 0.310 |
Why?
| | Radiologists | 3 | 2024 | 61 | 0.310 |
Why?
| | Myocardium | 5 | 2018 | 934 | 0.300 |
Why?
| | Disease Progression | 7 | 2019 | 2864 | 0.300 |
Why?
| | Periodicals as Topic | 1 | 2012 | 209 | 0.300 |
Why?
| | Cystadenocarcinoma | 2 | 2023 | 4 | 0.300 |
Why?
| | Software | 4 | 2018 | 680 | 0.290 |
Why?
| | Autoimmune Diseases | 1 | 2013 | 468 | 0.290 |
Why?
| | Kidney Transplantation | 2 | 2025 | 712 | 0.290 |
Why?
| | Ventricular Dysfunction, Right | 2 | 2025 | 248 | 0.280 |
Why?
| | Solitary Fibrous Tumors | 1 | 2008 | 3 | 0.280 |
Why?
| | Magnetic Resonance Imaging, Interventional | 1 | 2008 | 30 | 0.280 |
Why?
| | Secretin | 3 | 2019 | 6 | 0.280 |
Why?
| | Eye Neoplasms | 1 | 2008 | 30 | 0.280 |
Why?
| | Artificial Intelligence | 3 | 2022 | 381 | 0.270 |
Why?
| | Radiographic Image Enhancement | 2 | 2012 | 57 | 0.270 |
Why?
| | Chi-Square Distribution | 6 | 2017 | 527 | 0.260 |
Why?
| | Heart Atria | 2 | 2018 | 141 | 0.260 |
Why?
| | Sentinel Surveillance | 2 | 2018 | 46 | 0.260 |
Why?
| | Drug Delivery Systems | 1 | 2011 | 381 | 0.260 |
Why?
| | Rectum | 3 | 2020 | 182 | 0.250 |
Why?
| | Leiomyomatosis | 1 | 2007 | 4 | 0.250 |
Why?
| | Adolescent | 17 | 2026 | 22529 | 0.250 |
Why?
| | Neovascularization, Pathologic | 2 | 2008 | 286 | 0.250 |
Why?
| | Psoas Muscles | 3 | 2015 | 14 | 0.240 |
Why?
| | Myocardial Contraction | 2 | 2018 | 293 | 0.240 |
Why?
| | Pancreatectomy | 5 | 2020 | 289 | 0.240 |
Why?
| | RNA, Small Cytoplasmic | 1 | 2026 | 7 | 0.240 |
Why?
| | Antibodies, Antinuclear | 1 | 2026 | 62 | 0.240 |
Why?
| | Ventricular Outflow Obstruction | 2 | 2016 | 38 | 0.230 |
Why?
| | Ribonucleoproteins | 1 | 2026 | 89 | 0.220 |
Why?
| | Kidney Tubules | 1 | 2026 | 118 | 0.220 |
Why?
| | Models, Statistical | 3 | 2019 | 671 | 0.220 |
Why?
| | Liver Failure | 2 | 2016 | 83 | 0.220 |
Why?
| | Amyloidosis | 1 | 2025 | 44 | 0.210 |
Why?
| | Proteinuria | 1 | 2025 | 104 | 0.210 |
Why?
| | Disease Models, Animal | 4 | 2020 | 4560 | 0.210 |
Why?
| | Collateral Circulation | 1 | 2004 | 20 | 0.210 |
Why?
| | Cardiomyopathies | 2 | 2025 | 335 | 0.210 |
Why?
| | Scleroderma, Systemic | 1 | 2025 | 123 | 0.210 |
Why?
| | Computed Tomography Angiography | 1 | 2025 | 146 | 0.210 |
Why?
| | Pancreas, Exocrine | 1 | 2024 | 7 | 0.210 |
Why?
| | Rats, Sprague-Dawley | 2 | 2020 | 2524 | 0.200 |
Why?
| | Protons | 4 | 2020 | 96 | 0.200 |
Why?
| | Hypertension, Portal | 1 | 2004 | 66 | 0.200 |
Why?
| | Safety Management | 1 | 2024 | 125 | 0.200 |
Why?
| | Carcinoma, Papillary | 2 | 2014 | 77 | 0.200 |
Why?
| | Hepatic Veins | 1 | 2003 | 32 | 0.200 |
Why?
| | Atrophy | 3 | 2026 | 199 | 0.190 |
Why?
| | Feasibility Studies | 7 | 2024 | 1111 | 0.190 |
Why?
| | Cholecystitis, Acute | 1 | 2023 | 26 | 0.190 |
Why?
| | Pulmonary Embolism | 1 | 2025 | 241 | 0.190 |
Why?
| | Colitis, Ulcerative | 1 | 2024 | 148 | 0.190 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2024 | 138 | 0.190 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2023 | 61 | 0.190 |
Why?
| | Severity of Illness Index | 5 | 2026 | 2930 | 0.190 |
Why?
| | alpha-Fetoproteins | 2 | 2013 | 42 | 0.190 |
Why?
| | Pancreatitis, Chronic | 2 | 2020 | 64 | 0.190 |
Why?
| | Electrocardiography | 4 | 2020 | 665 | 0.190 |
Why?
| | Hemangioma, Cavernous | 1 | 2022 | 13 | 0.180 |
Why?
| | Kasabach-Merritt Syndrome | 1 | 2022 | 8 | 0.180 |
Why?
| | Cysts | 1 | 2023 | 112 | 0.180 |
Why?
| | Time Factors | 11 | 2018 | 7123 | 0.180 |
Why?
| | Statistics, Nonparametric | 5 | 2019 | 428 | 0.180 |
Why?
| | Atrial Fibrillation | 2 | 2018 | 558 | 0.180 |
Why?
| | Graft Rejection | 1 | 2025 | 521 | 0.180 |
Why?
| | Hemodynamics | 2 | 2025 | 1118 | 0.180 |
Why?
| | Ultrasonography, Mammary | 1 | 2021 | 17 | 0.170 |
Why?
| | Pandemics | 2 | 2020 | 1707 | 0.170 |
Why?
| | Melanoma | 1 | 2008 | 759 | 0.170 |
Why?
| | Single-Blind Method | 2 | 2017 | 318 | 0.170 |
Why?
| | Nuclear Medicine | 1 | 2021 | 9 | 0.170 |
Why?
| | Biomedical Research | 2 | 2022 | 717 | 0.170 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2022 | 147 | 0.170 |
Why?
| | Rats | 2 | 2020 | 5584 | 0.170 |
Why?
| | Cholestasis | 1 | 2023 | 214 | 0.160 |
Why?
| | Portal Vein | 4 | 2012 | 117 | 0.160 |
Why?
| | Semaphorins | 1 | 2021 | 37 | 0.160 |
Why?
| | Awards and Prizes | 1 | 2022 | 71 | 0.160 |
Why?
| | Crohn Disease | 1 | 2024 | 260 | 0.160 |
Why?
| | Reference Values | 2 | 2020 | 798 | 0.160 |
Why?
| | Gadolinium | 4 | 2021 | 84 | 0.160 |
Why?
| | Rabbits | 3 | 2011 | 652 | 0.160 |
Why?
| | Margins of Excision | 1 | 2020 | 50 | 0.160 |
Why?
| | Italy | 1 | 2020 | 116 | 0.160 |
Why?
| | Maryland | 3 | 2016 | 67 | 0.160 |
Why?
| | Regression Analysis | 3 | 2018 | 1001 | 0.160 |
Why?
| | Kidney Cortex | 1 | 2020 | 27 | 0.160 |
Why?
| | Cancer Care Facilities | 1 | 2021 | 48 | 0.160 |
Why?
| | Kidney Medulla | 1 | 2020 | 31 | 0.160 |
Why?
| | Thorax | 1 | 2020 | 51 | 0.160 |
Why?
| | Ferric Compounds | 2 | 2012 | 54 | 0.160 |
Why?
| | Inflammation | 1 | 2011 | 2878 | 0.160 |
Why?
| | Esophageal Mucosa | 1 | 2020 | 22 | 0.150 |
Why?
| | Mammography | 1 | 2021 | 166 | 0.150 |
Why?
| | Ursodeoxycholic Acid | 1 | 2019 | 17 | 0.150 |
Why?
| | Digestive System Neoplasms | 1 | 2019 | 9 | 0.150 |
Why?
| | Ultrasonography, Doppler, Color | 1 | 2019 | 37 | 0.150 |
Why?
| | Combined Modality Therapy | 6 | 2016 | 1266 | 0.150 |
Why?
| | Cardiac-Gated Imaging Techniques | 2 | 2016 | 21 | 0.150 |
Why?
| | Drug Therapy, Combination | 3 | 2024 | 1044 | 0.150 |
Why?
| | Recurrence | 2 | 2020 | 1138 | 0.150 |
Why?
| | Mutation | 4 | 2015 | 4075 | 0.150 |
Why?
| | Jaundice | 1 | 2019 | 10 | 0.150 |
Why?
| | Radiography | 6 | 2022 | 852 | 0.150 |
Why?
| | Prevalence | 5 | 2023 | 2865 | 0.150 |
Why?
| | Ovarian Neoplasms | 1 | 2025 | 595 | 0.150 |
Why?
| | Elasticity | 1 | 2019 | 189 | 0.140 |
Why?
| | Microspheres | 5 | 2016 | 142 | 0.140 |
Why?
| | Epidemiologic Methods | 1 | 2019 | 91 | 0.140 |
Why?
| | Jejunum | 1 | 2019 | 37 | 0.140 |
Why?
| | Vaccines | 1 | 2024 | 388 | 0.140 |
Why?
| | Chronic Disease | 4 | 2017 | 1808 | 0.140 |
Why?
| | Pyridines | 3 | 2021 | 609 | 0.140 |
Why?
| | Appendicitis | 1 | 2000 | 150 | 0.140 |
Why?
| | Postoperative Complications | 4 | 2016 | 2970 | 0.140 |
Why?
| | Mucins | 1 | 2019 | 75 | 0.140 |
Why?
| | Cardiac Imaging Techniques | 2 | 2018 | 24 | 0.140 |
Why?
| | Gastrointestinal Agents | 1 | 2019 | 65 | 0.140 |
Why?
| | Artifacts | 2 | 2016 | 143 | 0.140 |
Why?
| | Viscera | 1 | 2018 | 17 | 0.140 |
Why?
| | Brachytherapy | 1 | 2019 | 132 | 0.140 |
Why?
| | Pericardium | 1 | 2018 | 59 | 0.140 |
Why?
| | Logistic Models | 4 | 2026 | 2134 | 0.130 |
Why?
| | Equipment Safety | 1 | 2017 | 38 | 0.130 |
Why?
| | Caloric Restriction | 1 | 2019 | 133 | 0.130 |
Why?
| | Animals | 10 | 2020 | 38030 | 0.130 |
Why?
| | Hemochromatosis | 1 | 2017 | 9 | 0.130 |
Why?
| | Disease Susceptibility | 1 | 2019 | 344 | 0.130 |
Why?
| | Ventricular Flutter | 1 | 2017 | 2 | 0.130 |
Why?
| | Sepsis | 1 | 2024 | 664 | 0.130 |
Why?
| | Tomography, Emission-Computed | 2 | 2010 | 71 | 0.130 |
Why?
| | Metastasectomy | 1 | 2017 | 19 | 0.130 |
Why?
| | Pulmonary Veins | 1 | 2018 | 107 | 0.130 |
Why?
| | Adrenocortical Adenoma | 1 | 2016 | 2 | 0.130 |
Why?
| | Referral and Consultation | 2 | 2013 | 867 | 0.120 |
Why?
| | Lymphography | 1 | 2016 | 13 | 0.120 |
Why?
| | Breath Holding | 1 | 2016 | 10 | 0.120 |
Why?
| | Lung | 2 | 2020 | 4106 | 0.120 |
Why?
| | Radiotherapy | 2 | 2008 | 204 | 0.120 |
Why?
| | Incidence | 6 | 2020 | 2923 | 0.120 |
Why?
| | Obesity | 3 | 2023 | 3116 | 0.120 |
Why?
| | Electric Countershock | 1 | 2017 | 126 | 0.120 |
Why?
| | Motion | 1 | 2016 | 94 | 0.120 |
Why?
| | Pacemaker, Artificial | 1 | 2017 | 128 | 0.120 |
Why?
| | Evaluation Studies as Topic | 1 | 2016 | 164 | 0.120 |
Why?
| | Neoplasms, Second Primary | 1 | 2017 | 102 | 0.120 |
Why?
| | Disease Management | 3 | 2015 | 653 | 0.120 |
Why?
| | Body Water | 1 | 2016 | 23 | 0.120 |
Why?
| | Pancreatic Juice | 2 | 2012 | 3 | 0.120 |
Why?
| | Benzamides | 1 | 2017 | 226 | 0.120 |
Why?
| | Coronary Circulation | 2 | 2015 | 134 | 0.120 |
Why?
| | Carcinoid Tumor | 2 | 2008 | 21 | 0.120 |
Why?
| | Platelet Count | 1 | 2016 | 94 | 0.120 |
Why?
| | Primary Prevention | 1 | 2018 | 219 | 0.120 |
Why?
| | Azacitidine | 1 | 2017 | 157 | 0.120 |
Why?
| | Multivariate Analysis | 6 | 2017 | 1547 | 0.120 |
Why?
| | Echocardiography | 2 | 2016 | 647 | 0.120 |
Why?
| | Phosphorus | 1 | 2016 | 90 | 0.120 |
Why?
| | Adrenal Cortex Neoplasms | 1 | 2016 | 70 | 0.110 |
Why?
| | Adiposity | 1 | 2020 | 532 | 0.110 |
Why?
| | Pancreatitis, Acute Necrotizing | 1 | 2015 | 14 | 0.110 |
Why?
| | Hepatopulmonary Syndrome | 1 | 2015 | 23 | 0.110 |
Why?
| | Bariatric Surgery | 1 | 2019 | 252 | 0.110 |
Why?
| | Fractures, Spontaneous | 2 | 2005 | 15 | 0.110 |
Why?
| | Telomere Homeostasis | 1 | 2015 | 33 | 0.110 |
Why?
| | Bone Neoplasms | 1 | 2018 | 259 | 0.110 |
Why?
| | Hospital Costs | 1 | 2016 | 125 | 0.110 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2020 | 641 | 0.110 |
Why?
| | Body Composition | 1 | 2019 | 693 | 0.110 |
Why?
| | Digestive System Surgical Procedures | 1 | 2016 | 112 | 0.110 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2016 | 124 | 0.110 |
Why?
| | Insulin | 1 | 2026 | 2512 | 0.110 |
Why?
| | Fractures, Stress | 2 | 2005 | 31 | 0.110 |
Why?
| | Telomere | 2 | 2015 | 287 | 0.110 |
Why?
| | Preoperative Care | 3 | 2024 | 380 | 0.110 |
Why?
| | Patient Care Team | 1 | 2021 | 696 | 0.110 |
Why?
| | Frail Elderly | 1 | 2015 | 136 | 0.110 |
Why?
| | Image-Guided Biopsy | 1 | 2014 | 41 | 0.110 |
Why?
| | Acrylic Resins | 2 | 2012 | 46 | 0.110 |
Why?
| | Biliary Tract | 2 | 2012 | 14 | 0.110 |
Why?
| | Disease-Free Survival | 4 | 2022 | 767 | 0.110 |
Why?
| | Gene Expression | 1 | 2019 | 1476 | 0.110 |
Why?
| | Gelatin | 2 | 2012 | 56 | 0.100 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2014 | 109 | 0.100 |
Why?
| | Abdomen, Acute | 1 | 2014 | 21 | 0.100 |
Why?
| | Antibiotics, Antineoplastic | 2 | 2012 | 140 | 0.100 |
Why?
| | Fissure in Ano | 1 | 2013 | 4 | 0.100 |
Why?
| | Genetic Predisposition to Disease | 5 | 2013 | 2378 | 0.100 |
Why?
| | Cholecystitis | 1 | 2014 | 24 | 0.100 |
Why?
| | Critical Illness | 1 | 2020 | 900 | 0.100 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2013 | 25 | 0.100 |
Why?
| | Decision Support Techniques | 1 | 2018 | 477 | 0.100 |
Why?
| | Linear Models | 3 | 2011 | 845 | 0.100 |
Why?
| | Dyspnea | 1 | 2015 | 250 | 0.100 |
Why?
| | Delayed-Action Preparations | 1 | 2014 | 189 | 0.100 |
Why?
| | Ventricular Remodeling | 1 | 2016 | 278 | 0.100 |
Why?
| | Hypertension, Pulmonary | 1 | 2025 | 1957 | 0.100 |
Why?
| | Carcinoma, Transitional Cell | 2 | 2005 | 68 | 0.100 |
Why?
| | Rectal Fistula | 1 | 2013 | 27 | 0.100 |
Why?
| | Analysis of Variance | 2 | 2013 | 1300 | 0.100 |
Why?
| | Weight Loss | 1 | 2019 | 858 | 0.100 |
Why?
| | Pattern Recognition, Automated | 1 | 2013 | 74 | 0.100 |
Why?
| | Tetrazoles | 1 | 2013 | 50 | 0.100 |
Why?
| | Pelvic Neoplasms | 1 | 2013 | 24 | 0.100 |
Why?
| | Cystic Fibrosis | 1 | 2023 | 1161 | 0.100 |
Why?
| | Postoperative Period | 3 | 2016 | 351 | 0.100 |
Why?
| | Abdominal Neoplasms | 1 | 2013 | 47 | 0.100 |
Why?
| | Protein Phosphatase 1 | 1 | 2013 | 32 | 0.090 |
Why?
| | Academic Medical Centers | 2 | 2013 | 554 | 0.090 |
Why?
| | Liver Circulation | 1 | 2012 | 12 | 0.090 |
Why?
| | Iohexol | 1 | 2012 | 23 | 0.090 |
Why?
| | Endoscopy, Digestive System | 2 | 2024 | 142 | 0.090 |
Why?
| | GTP-Binding Protein alpha Subunits, Gs | 1 | 2012 | 9 | 0.090 |
Why?
| | Acute Disease | 3 | 2023 | 1036 | 0.090 |
Why?
| | Lipase | 1 | 2013 | 75 | 0.090 |
Why?
| | Prednisone | 1 | 2013 | 224 | 0.090 |
Why?
| | Polyvinyls | 1 | 2012 | 19 | 0.090 |
Why?
| | Vascular Neoplasms | 1 | 2012 | 18 | 0.090 |
Why?
| | Ventricular Function, Left | 1 | 2016 | 542 | 0.090 |
Why?
| | Imidazoles | 1 | 2013 | 247 | 0.090 |
Why?
| | Computer Simulation | 1 | 2016 | 1003 | 0.090 |
Why?
| | Electrophysiologic Techniques, Cardiac | 3 | 2018 | 82 | 0.090 |
Why?
| | DNA Methylation | 1 | 2017 | 674 | 0.090 |
Why?
| | Peer Review, Research | 1 | 2012 | 36 | 0.090 |
Why?
| | Glucocorticoids | 2 | 2013 | 531 | 0.090 |
Why?
| | Bibliometrics | 1 | 2012 | 66 | 0.090 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2012 | 81 | 0.090 |
Why?
| | Editorial Policies | 1 | 2012 | 45 | 0.090 |
Why?
| | World Health Organization | 2 | 2022 | 104 | 0.090 |
Why?
| | Intra-Abdominal Fat | 2 | 2024 | 101 | 0.080 |
Why?
| | Precancerous Conditions | 1 | 2012 | 166 | 0.080 |
Why?
| | Myocardial Ischemia | 1 | 2013 | 285 | 0.080 |
Why?
| | Angiogenesis Inhibitors | 1 | 2012 | 238 | 0.080 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2024 | 337 | 0.080 |
Why?
| | Practice Patterns, Physicians' | 3 | 2021 | 1371 | 0.080 |
Why?
| | Respiration | 2 | 2017 | 206 | 0.080 |
Why?
| | Coronary Vessels | 1 | 2012 | 246 | 0.080 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2024 | 423 | 0.080 |
Why?
| | Sclerosis | 1 | 2010 | 11 | 0.080 |
Why?
| | Guidelines as Topic | 1 | 2012 | 266 | 0.080 |
Why?
| | Urinary Bladder | 2 | 2022 | 195 | 0.080 |
Why?
| | Polymorphism, Genetic | 1 | 2013 | 614 | 0.080 |
Why?
| | Regional Blood Flow | 1 | 2012 | 514 | 0.080 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2014 | 2028 | 0.080 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2013 | 425 | 0.080 |
Why?
| | Splenectomy | 1 | 2010 | 61 | 0.080 |
Why?
| | Pituitary-Adrenal System | 1 | 2011 | 164 | 0.080 |
Why?
| | Cell Proliferation | 1 | 2017 | 2507 | 0.080 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 2011 | 199 | 0.070 |
Why?
| | Glomerular Filtration Rate | 2 | 2025 | 765 | 0.070 |
Why?
| | Saliva | 1 | 2011 | 246 | 0.070 |
Why?
| | Immunoglobulin G | 1 | 2013 | 892 | 0.070 |
Why?
| | Ultrasonic Therapy | 1 | 2009 | 16 | 0.070 |
Why?
| | Hydrocortisone | 1 | 2011 | 298 | 0.070 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2012 | 534 | 0.070 |
Why?
| | Pilot Projects | 3 | 2019 | 1891 | 0.070 |
Why?
| | Heart | 3 | 2017 | 626 | 0.070 |
Why?
| | Exercise | 2 | 2019 | 2198 | 0.070 |
Why?
| | Baltimore | 3 | 2015 | 72 | 0.070 |
Why?
| | Stroke Volume | 2 | 2022 | 654 | 0.070 |
Why?
| | Organoplatinum Compounds | 2 | 2019 | 65 | 0.070 |
Why?
| | Carcinoma, Islet Cell | 1 | 2008 | 1 | 0.070 |
Why?
| | Lipids | 1 | 2013 | 707 | 0.070 |
Why?
| | Brain | 1 | 2020 | 2947 | 0.070 |
Why?
| | Internet | 1 | 2012 | 689 | 0.060 |
Why?
| | Intestinal Neoplasms | 2 | 2004 | 30 | 0.060 |
Why?
| | Catheterization, Peripheral | 1 | 2008 | 120 | 0.060 |
Why?
| | Soft Tissue Neoplasms | 1 | 2008 | 131 | 0.060 |
Why?
| | Circadian Rhythm | 1 | 2011 | 512 | 0.060 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2012 | 992 | 0.060 |
Why?
| | Membrane Proteins | 1 | 2013 | 1164 | 0.060 |
Why?
| | Duodenum | 2 | 2019 | 77 | 0.060 |
Why?
| | Pyridoxal Phosphate | 1 | 2005 | 20 | 0.060 |
Why?
| | Uterus | 1 | 2007 | 227 | 0.060 |
Why?
| | Gallbladder Diseases | 1 | 2005 | 11 | 0.060 |
Why?
| | Edetic Acid | 1 | 2005 | 47 | 0.060 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 2007 | 189 | 0.060 |
Why?
| | Cross-Sectional Studies | 4 | 2022 | 5904 | 0.060 |
Why?
| | Sus scrofa | 2 | 2016 | 65 | 0.060 |
Why?
| | Ultrasonography, Doppler | 1 | 2025 | 126 | 0.050 |
Why?
| | Iodized Oil | 3 | 2012 | 3 | 0.050 |
Why?
| | Case-Control Studies | 3 | 2019 | 3623 | 0.050 |
Why?
| | Portography | 1 | 2004 | 7 | 0.050 |
Why?
| | Splenic Vein | 1 | 2004 | 2 | 0.050 |
Why?
| | Portal System | 1 | 2004 | 12 | 0.050 |
Why?
| | Mesenteric Vascular Occlusion | 1 | 2004 | 5 | 0.050 |
Why?
| | Myometrium | 1 | 2005 | 38 | 0.050 |
Why?
| | Esophagectomy | 1 | 2025 | 135 | 0.050 |
Why?
| | Receptors, Somatostatin | 1 | 2004 | 24 | 0.050 |
Why?
| | Somatostatin | 1 | 2004 | 53 | 0.050 |
Why?
| | Age Factors | 3 | 2018 | 3342 | 0.050 |
Why?
| | Mesenteric Veins | 1 | 2004 | 24 | 0.050 |
Why?
| | Arteriosclerosis | 1 | 2004 | 83 | 0.050 |
Why?
| | Calibration | 1 | 2024 | 152 | 0.050 |
Why?
| | Body Mass Index | 3 | 2019 | 2445 | 0.050 |
Why?
| | Peripheral Vascular Diseases | 1 | 2004 | 104 | 0.050 |
Why?
| | Ovary | 1 | 2025 | 233 | 0.050 |
Why?
| | Constriction, Pathologic | 1 | 2004 | 249 | 0.050 |
Why?
| | Carcinosarcoma | 1 | 2003 | 23 | 0.050 |
Why?
| | Ipilimumab | 1 | 2023 | 40 | 0.050 |
Why?
| | Mycophenolic Acid | 1 | 2024 | 120 | 0.050 |
Why?
| | Pelvis | 1 | 2024 | 125 | 0.050 |
Why?
| | Creatinine | 1 | 2025 | 515 | 0.050 |
Why?
| | Common Bile Duct | 1 | 2022 | 14 | 0.050 |
Why?
| | Intestine, Small | 1 | 2004 | 167 | 0.050 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2006 | 394 | 0.050 |
Why?
| | Heart Aneurysm | 1 | 2002 | 12 | 0.050 |
Why?
| | Child | 5 | 2026 | 22707 | 0.050 |
Why?
| | X-Rays | 1 | 2022 | 27 | 0.050 |
Why?
| | Kinetics | 2 | 2017 | 1567 | 0.040 |
Why?
| | Registries | 3 | 2018 | 2406 | 0.040 |
Why?
| | Financing, Organized | 1 | 2022 | 36 | 0.040 |
Why?
| | Heart Failure | 1 | 2015 | 2326 | 0.040 |
Why?
| | Hormones | 1 | 2022 | 135 | 0.040 |
Why?
| | Research Support as Topic | 1 | 2022 | 80 | 0.040 |
Why?
| | Financing, Government | 1 | 2022 | 53 | 0.040 |
Why?
| | Morbidity | 2 | 2013 | 322 | 0.040 |
Why?
| | Aorta, Thoracic | 1 | 2004 | 286 | 0.040 |
Why?
| | Anilides | 1 | 2021 | 84 | 0.040 |
Why?
| | Pedigree | 2 | 2012 | 515 | 0.040 |
Why?
| | B7-H1 Antigen | 1 | 2023 | 244 | 0.040 |
Why?
| | Fluoroscopy | 1 | 2021 | 180 | 0.040 |
Why?
| | Cholinergic Agents | 1 | 2020 | 18 | 0.040 |
Why?
| | Patient Selection | 2 | 2017 | 738 | 0.040 |
Why?
| | Breast | 1 | 2021 | 156 | 0.040 |
Why?
| | Mitomycin | 2 | 2012 | 32 | 0.040 |
Why?
| | Monitoring, Physiologic | 1 | 2002 | 288 | 0.040 |
Why?
| | Preoperative Period | 1 | 2020 | 149 | 0.040 |
Why?
| | Length of Stay | 2 | 2016 | 1349 | 0.040 |
Why?
| | Appendectomy | 1 | 2000 | 90 | 0.040 |
Why?
| | Aorta | 1 | 2023 | 440 | 0.040 |
Why?
| | Islets of Langerhans Transplantation | 1 | 2020 | 70 | 0.040 |
Why?
| | Precision Medicine | 1 | 2024 | 459 | 0.040 |
Why?
| | Hepatitis C | 1 | 2002 | 256 | 0.040 |
Why?
| | Cachexia | 1 | 2020 | 74 | 0.040 |
Why?
| | Gastroplasty | 1 | 2019 | 32 | 0.040 |
Why?
| | Emergencies | 1 | 2000 | 174 | 0.040 |
Why?
| | Surveys and Questionnaires | 1 | 2012 | 6066 | 0.040 |
Why?
| | Data Accuracy | 1 | 2019 | 65 | 0.040 |
Why?
| | Pancreatic Function Tests | 1 | 2019 | 3 | 0.040 |
Why?
| | Immunosuppressive Agents | 1 | 2024 | 838 | 0.040 |
Why?
| | Longitudinal Studies | 2 | 2018 | 2953 | 0.040 |
Why?
| | Absorptiometry, Photon | 1 | 2019 | 277 | 0.030 |
Why?
| | Risk | 1 | 2021 | 919 | 0.030 |
Why?
| | Cisplatin | 2 | 2012 | 345 | 0.030 |
Why?
| | Insulin Resistance | 1 | 2026 | 1244 | 0.030 |
Why?
| | Gastric Bypass | 1 | 2019 | 126 | 0.030 |
Why?
| | Paclitaxel | 1 | 2019 | 257 | 0.030 |
Why?
| | Electric Power Supplies | 1 | 2017 | 47 | 0.030 |
Why?
| | Neoplasm Metastasis | 2 | 2012 | 688 | 0.030 |
Why?
| | Global Health | 1 | 2020 | 403 | 0.030 |
Why?
| | Equipment Failure | 1 | 2017 | 115 | 0.030 |
Why?
| | HCT116 Cells | 1 | 2017 | 76 | 0.030 |
Why?
| | Infant | 3 | 2022 | 10077 | 0.030 |
Why?
| | Zinc Finger Protein Gli3 | 1 | 2016 | 3 | 0.030 |
Why?
| | Camptothecin | 1 | 2017 | 138 | 0.030 |
Why?
| | Electrocardiography, Ambulatory | 1 | 2017 | 63 | 0.030 |
Why?
| | Xenopus Proteins | 1 | 2016 | 36 | 0.030 |
Why?
| | Pain | 1 | 2022 | 789 | 0.030 |
Why?
| | Radionuclide Imaging | 2 | 2008 | 115 | 0.030 |
Why?
| | Hemorrhage | 1 | 2022 | 822 | 0.030 |
Why?
| | Databases, Factual | 2 | 2016 | 1490 | 0.030 |
Why?
| | Phenotype | 2 | 2015 | 3155 | 0.030 |
Why?
| | Equipment Failure Analysis | 1 | 2016 | 124 | 0.030 |
Why?
| | Consensus | 1 | 2018 | 477 | 0.030 |
Why?
| | Exudates and Transudates | 1 | 2015 | 12 | 0.030 |
Why?
| | Machine Learning | 1 | 2021 | 587 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2022 | 924 | 0.030 |
Why?
| | Advisory Committees | 1 | 2017 | 229 | 0.030 |
Why?
| | Species Specificity | 1 | 2016 | 546 | 0.030 |
Why?
| | Cell Line, Tumor | 2 | 2017 | 3542 | 0.030 |
Why?
| | Echocardiography, Stress | 1 | 2015 | 29 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2017 | 782 | 0.030 |
Why?
| | Models, Animal | 1 | 2016 | 393 | 0.030 |
Why?
| | Heterozygote | 1 | 2015 | 313 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2021 | 946 | 0.030 |
Why?
| | Sex Factors | 2 | 2015 | 2105 | 0.030 |
Why?
| | Equipment Design | 1 | 2016 | 525 | 0.030 |
Why?
| | Compressive Strength | 1 | 2014 | 72 | 0.030 |
Why?
| | Biomechanical Phenomena | 1 | 2017 | 857 | 0.030 |
Why?
| | Autoradiography | 1 | 2013 | 66 | 0.030 |
Why?
| | Geriatric Assessment | 1 | 2015 | 239 | 0.020 |
Why?
| | Injections, Intra-Arterial | 1 | 2013 | 26 | 0.020 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 363 | 0.020 |
Why?
| | Blood Cell Count | 1 | 2013 | 55 | 0.020 |
Why?
| | Anaplasia | 1 | 2013 | 7 | 0.020 |
Why?
| | Netherlands | 1 | 2013 | 84 | 0.020 |
Why?
| | Epithelial Cells | 1 | 2020 | 1131 | 0.020 |
Why?
| | Research Design | 2 | 2011 | 1137 | 0.020 |
Why?
| | Fractional Flow Reserve, Myocardial | 1 | 2013 | 10 | 0.020 |
Why?
| | Phospholipases A2, Calcium-Independent | 1 | 2013 | 18 | 0.020 |
Why?
| | Telomerase | 1 | 2015 | 246 | 0.020 |
Why?
| | Pressure | 1 | 2014 | 226 | 0.020 |
Why?
| | Molecular Imaging | 1 | 2013 | 57 | 0.020 |
Why?
| | Cicatrix | 1 | 2013 | 69 | 0.020 |
Why?
| | Chromogranins | 1 | 2012 | 13 | 0.020 |
Why?
| | Acyltransferases | 1 | 2013 | 78 | 0.020 |
Why?
| | Radiology, Interventional | 1 | 2013 | 49 | 0.020 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2012 | 44 | 0.020 |
Why?
| | Mutant Proteins | 1 | 2012 | 105 | 0.020 |
Why?
| | Microcirculation | 1 | 2013 | 142 | 0.020 |
Why?
| | Epigenesis, Genetic | 1 | 2017 | 679 | 0.020 |
Why?
| | Heredity | 1 | 2012 | 13 | 0.020 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2013 | 325 | 0.020 |
Why?
| | DNA, Neoplasm | 1 | 2012 | 158 | 0.020 |
Why?
| | Choice Behavior | 1 | 2013 | 180 | 0.020 |
Why?
| | Bilirubin | 1 | 2012 | 99 | 0.020 |
Why?
| | Mexican Americans | 1 | 2013 | 119 | 0.020 |
Why?
| | Benzenesulfonates | 1 | 2011 | 23 | 0.020 |
Why?
| | Sampling Studies | 1 | 2011 | 98 | 0.020 |
Why?
| | Gene Frequency | 1 | 2013 | 487 | 0.020 |
Why?
| | China | 1 | 2012 | 270 | 0.020 |
Why?
| | Hepatitis B, Chronic | 1 | 2011 | 22 | 0.020 |
Why?
| | Ligands | 1 | 2013 | 665 | 0.020 |
Why?
| | Treatment Failure | 1 | 2012 | 360 | 0.020 |
Why?
| | Nutrition Surveys | 1 | 2013 | 279 | 0.020 |
Why?
| | Asymptomatic Diseases | 1 | 2012 | 104 | 0.020 |
Why?
| | Allostasis | 1 | 2011 | 17 | 0.020 |
Why?
| | Early Diagnosis | 1 | 2012 | 251 | 0.020 |
Why?
| | Europe | 1 | 2012 | 418 | 0.020 |
Why?
| | Antibiotic Prophylaxis | 1 | 2012 | 134 | 0.020 |
Why?
| | Genetic Association Studies | 1 | 2013 | 369 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2011 | 330 | 0.020 |
Why?
| | Vasodilator Agents | 1 | 2013 | 330 | 0.020 |
Why?
| | Adrenal Glands | 1 | 2011 | 76 | 0.020 |
Why?
| | Canada | 1 | 2012 | 431 | 0.020 |
Why?
| | Gastroenterology | 1 | 2013 | 191 | 0.020 |
Why?
| | General Surgery | 1 | 2013 | 206 | 0.020 |
Why?
| | Medical Oncology | 1 | 2013 | 339 | 0.020 |
Why?
| | Action Potentials | 1 | 2013 | 502 | 0.020 |
Why?
| | Hepatitis C, Chronic | 1 | 2011 | 153 | 0.020 |
Why?
| | Molecular Targeted Therapy | 1 | 2012 | 439 | 0.020 |
Why?
| | Sodium Isotopes | 1 | 2009 | 2 | 0.020 |
Why?
| | Neoplasm Proteins | 1 | 2012 | 441 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2013 | 1716 | 0.020 |
Why?
| | Dexamethasone | 1 | 2011 | 365 | 0.020 |
Why?
| | Thrombosis | 1 | 2012 | 400 | 0.020 |
Why?
| | Tissue Distribution | 1 | 2008 | 335 | 0.020 |
Why?
| | Bile Ducts, Extrahepatic | 1 | 2006 | 20 | 0.020 |
Why?
| | Healthcare Disparities | 1 | 2013 | 735 | 0.020 |
Why?
| | Femoral Artery | 1 | 2007 | 190 | 0.010 |
Why?
| | Blood Glucose | 1 | 2016 | 2341 | 0.010 |
Why?
| | Mass Screening | 1 | 2014 | 1360 | 0.010 |
Why?
| | Gallbladder | 1 | 2005 | 15 | 0.010 |
Why?
| | Child, Preschool | 2 | 2014 | 11853 | 0.010 |
Why?
| | Tissue Survival | 1 | 2005 | 16 | 0.010 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2019 | 2588 | 0.010 |
Why?
| | Adenoma, Islet Cell | 1 | 2004 | 6 | 0.010 |
Why?
| | Indium Radioisotopes | 1 | 2004 | 12 | 0.010 |
Why?
| | Bone Diseases | 1 | 2005 | 61 | 0.010 |
Why?
| | Radiography, Interventional | 1 | 2005 | 128 | 0.010 |
Why?
| | Mice | 1 | 2020 | 18329 | 0.010 |
Why?
| | Aneurysm, False | 1 | 2002 | 46 | 0.010 |
Why?
| | Palliative Care | 1 | 2005 | 1020 | 0.010 |
Why?
| | Myocardial Infarction | 1 | 2002 | 1210 | 0.010 |
Why?
|
|
Kamel's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|